Moderna shares surged 16% Wednesday to their highest level since 2024 after the company agreed to pay up to $2.25 billion to ...

Moderna has outperformed the Dow over the past year, yet Wall Street analysts maintain a cautious outlook on the stock’s ...

The deal would provide ‘certainty’ for Moderna’s vaccine portfolio.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Moderna (MRNA) stock has shed roughly 90% of its value since its 2021 peak.

If you are wondering whether Moderna's share price really reflects what the business is worth today, you are not alone. That ...

This prompts a reassessment of the stock’s value to determine if this represents a genuine opportunity or a potential trap.

The company has had its ups -- the approval of its respiratory syncytial virus (RSV) vaccine back in 2024 -- and its downs -- the failure of its cytomegalovirus (CMV) vaccine candidate in a phase 3 ...

Including the settlement payment, Moderna now expects to end 2026 with between $4.5 billion and $5 billion in cash and cash ...

Two stocks are standing out in premarket trading this Wednesday morning. Moderna (Nasdaq: MRNA) is up 8.9% and Ross Stores ...

The company settles to resolve patent litigation related to its Covid-19 vaccine, removing an overhang for shares.

A few years ago, investors rushed to buy Moderna (NASDAQ: MRNA) stock. The biotech company had brought its coronavirus vaccine to market in less than a year and quickly saw earnings take off. The ...